Specific delivery of idarubicin to HER2-positive breast cancerous cell line by trastuzumab-conjugated liposomes
Authors:
- Mansour AminMAMansour Amin
- Aminollah PourshohodAPAminollah Pourshohod
- Alireza KheirollahAKAlireza Kheirollah
- Moslem AfrakhtehMAMoslem Afrakhteh
- Fatollah Gholami-BorujeniFGFatollah Gholami-Borujeni
- Majid ZeinaliMZMajid Zeinali
- Mostafa JamalanMJMostafa Jamalan
- 1 October 2018
- journal article
- research article
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 47, 209-214
Abstract
No abstract availableKeywords
Funding Information
- Ahvaz Jundishapur University of Medical Sciences (CMRC-119)
This publication has 48 references indexed in Scilit:
- Preparation of DOPC and DPPC Supported Planar Lipid Bilayers for Atomic Force Microscopy and Atomic Force SpectroscopyInternational Journal of Molecular Sciences, 2013
- Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cellsBreast Cancer Research and Treatment, 2010
- A Novel Peptide Enhances Therapeutic Efficacy of Liposomal Anti-Cancer Drugs in Mice Models of Human Lung CancerPLOS ONE, 2009
- Nanoparticle therapeutics: an emerging treatment modality for cancerNature Reviews Drug Discovery, 2008
- Epidermal growth factor receptor (EGFR) signaling in cancerGene, 2006
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimersThe EMBO Journal, 1998
- Oral IdarubicinDrugs & Aging, 1997
- ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976